using i/o in msi-h tumors in mcrc
Published 4 years ago • 91 plays • Length 8:04Download video MP4
Download video MP3
Similar videos
-
8:34
relapsed/refractory mcrc: immunotherapy in msi-high tumors
-
9:02
pembrolizumab in msi-h crc tumors
-
4:00
immunotherapy combinations in msi and mss mcrc
-
6:54
key takeaway 7: role of immunotherapy in msi-high mcrc
-
5:19
i-o therapy in mcrc: ipilimumab nivolumab
-
1:11
checkmate-8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
1:08
dr. overman discusses nivolumab in patients with dmmr/msi h mcrc
-
1:04
dr. halfdanarson on the keynote-177 trial in msi-h/dmmr mcrc
-
1:35
dr. chu on the role of pembrolizumab in dmmr/msi-h mcrc
-
6:27
immunotherapy in msi-high pancreatic tumors
-
4:32
immunotherapy regimens in dmmr/msi-high metastatic crc
-
1:03
dr. nelson on the checkmate-142 trial in msi-h/dmmr mcrc
-
9:25
debate: msi high colon cancer - immunotherapy
-
5:41
role of immunotherapy in microsatellite-stable r/r mcrc
-
5:49
immunotherapy and msi status in colorectal cancer
-
2:32
dr. overman discusses updated findings of checkmate-142 in patients with msi-h mcrc
-
1:20
dr. saab on immunotherapy in msi-h gi malignancies
-
1:08
dr. ahn on the keynote-177 trial in newly diagnosed msi-h/dmmr mcrc
-
0:59
checkmate 8hw: hrqol outcomes of nivolumab and ipilimumab in msi-h/dmmr mcrc